Asymptote Ltd.

Cambridge, United Kingdom

Asymptote Ltd.

Cambridge, United Kingdom

Time filter

Source Type

Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 20.89K | Year: 2013

Cryopreservation is a method for the long term stabilisation of biological materials for use in medicine and science. However during cooling ice nucleation is an unpredictable process and samples are observed to nucleate over a wide range of temperature. It is known that when cryopreserving cells, induced ice nucleation is highly desirable to retain functionality of cells on thawing. This project will examine the feasibility of developing an ice nucleating coating for the inside of vessels used for cryopreservation which will overcome the problems caused by random ice nucleation and improve cell recovery on thawing. This technolgy also has potential application in the freeze drying of pharmaceuticals and in food freezing.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 24.47K | Year: 2013

In this project we propose to develop a portable, self charging , cryogenic vessel for the shipment and short term storage of frozen material. In particular, live vaccines for use in third world. Examples of the material include live attenuated vaccines in development for treatment of human malaria and leshmaniasis as well as several veterinary products. In 3rd world applications it has been estimated that up to 50% of vaccines are discarded because of real or percived thermal damage due to failure of the cold chain. We are proposing a new concept in cold chain equipment which would eliminate these distribution issues.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 922.37K | Year: 2014

This application relates to the development of the consumables and associated equipment to allow the widespread clinical delivery of a bioartificial liver (BAL). Since the liver is one of the few organs that can repair and regenerate, therapies enabling regenerative medicine, that is creating living functional tissues to repair or replace organ function lost due to damage, are expected to play a role in several areas of liver disease. A bioartificial liver machine can temporarily replace the functions of the liver, allowing the damaged liver to regenerate whilst protecting the patient’s other organs from the life-threatening damage that ensues during liver failure. If the toxicity can be mitigated, within 24 to 48 hours, the majority of liver cells will enter DNA synthesis, closely followed by mitosis enabling the liver to regenerate, restoring full function within a few days.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 118.30K | Year: 2016

In regenerative and transplantation medicine medicine a bottleneck limiting progress is that tissue engineered constructs cannot be manufactured on demand. Cryopreservation aims to overcome this problem, however whilst success has been achieved with cell suspensions, successful scale up of construct size has remained elusive. No methods exist that can protect complex biomasses from the severe stress they encounter during cooling and warming from liquid nitrogen (-196°C). We propose a new method, where non-Newtonian, shear- thickening fluids can be used to improve operational performance of cryopreservation. Shear thickening fluids are materials whose viscosity increases with shear stress, for example vibration. With the correct level of vibration, the material can change from a liquid to a solid instantly. We propose this as an effective material for extremely low temperature biological preservation. At the storage temperature, shear stress would be stopped as the material would remain solid (vitrified) due to the low temperatures. The shear-thickening materials make the process completely reversible.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 111.50K | Year: 2013

Freeze drying is a method used for the stabilisation of a range of medical products, it has been estimated that over 50% of current medical products are freeze-dried due to their instability in the liquid state. However there exist a range of recalcitrant materials which cannot be satisfactorily freeze dried using conventional technology. In this project we will determine the benefits of a new method of freeze drying. The benefits of this technology could range from an improvement in the quality of materials which can currently be freeze dried (enzymes, protein therapeutics) to the creation of new products, for example freeze dried stem cells for application in regenerative medicine


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Proof of Concept | Award Amount: 78.46K | Year: 2015

Cancer treatments are being transformed by T-Cell therapies and present a huge global opportunity. However, logistical problems transporting the cells to and from the patient are restricting the industry’s growth. There is an urgent need for a portable shipping device that combines; controlled sample freezing, temperature controlled shipping, data logging, short term frozen storage and thawing. This project will develop a basic prototype, free of liquid nitrogen, optimised for the shipping of T-cell therapies. This will be an electrically powered system based on a Stirling cryocooler, with a target isothermal hold temperature of -120°C. The system will be able to operate on mains power, a 12V vehicle supply or via an uninterruptable power supply (UPS). The storage chamber will be vacuum insulated and the device will maintain -100°C for 24 hrs when disconnected from all power. To allow transport of the source T-cells, the equipment will also be able to carry out the controlled rate freezing (CRF) of samples. The equipment will also act as a storage device at the clinical site, maintaining the sample temperature below -100°C until required for treatment. In discussions with a range of end users (academic and commercial) we have confirmed that there is currently no suitable cryogenic service for autologous treatments which can offer CRF of the source cells, temperature controlled transport, data logging, short term storage and thawing.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 269.06K | Year: 2015

The project brings together the technological expertise to develop a cost effective mass production and delivery a more effective biological solution to control pests with expertise in fungal cell processes and whole organism survival to ensure product long term shelf life whist retaining organism function. It combines improved product formulation with effectiveness to reduce crop losses and chemical pollution causing soil quality deterioration. The project will: Apply advanced technology to biological product development with the potential for transfer to other biological applications; Take improved laboratory knowledge to improve the cost effectiveness and efficacy to a product in the field; Develop formulations increase shelf life and confidence in the use of biological solutions to replace chemical pesticides; Produce a product appropriate for storage and use in developing economy countries; Reduce crop losses by utilisation of organisms that previously could not applied in the field


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 321.04K | Year: 2014

The project will develop a consistent, highly functional and biologically robust technology for the cryopreservation of cells in microtitre plates. These cells will be used in subsequent screening applications, for example drug safety testing. Many cell types are used for screening applications, with hepatocytes being widely used to investigate drug safety and metabolism in pharmaceutical research. Microtitre plates are used for screening; these plates have either 96 wells (200 µL per well) or 384 wells (25 µL per well). However, with the exception of robust cell types, cryopreservation of cells in microtitre plates is unsatisfactory. A high quality frozen poduct would be disruptive, lowering shipping costs considerably and giving greater flexibility to end users.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 592.28K | Year: 2012

Asymptote Ltd is proposing to develop the first GMP compliant cryogenic cold chain for the clinical delivery of regenerative medicine therapeutics. This project focuses on the key elements of the cold chain: controlled rate freezing of large volumes, short and long term frozen storage, and controlled thawing of large volumes. Cryopreservation of cells with high functionality on thawing is essential for cost effective cell production and geographically widespread clinical treatments, and this depends on accurate control of the freezing and thawing. This project will use Stirling cryocooler technology which has unique control ability and is able to meet the GMP requirement of regenerative medicine. It is intended to produce demonstrators for the key elements of the cold chain in collaboration with four centres developing different cell therapies.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 24.49K | Year: 2011

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Loading Asymptote Ltd. collaborators
Loading Asymptote Ltd. collaborators